Gerresheimer, innovative systems and solutions provider and global partner for the pharmaceutical, biotech and cosmetics industries, has successfully completed the acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group, announced in May 2024. The conclusion was preceded by the fulfillment of standard closing conditions. Bormioli Pharma has a portfolio of pharmaceutical primary packaging made of glass and plastic as well as closure solutions, accessories and dosing systems that is complementary to Gerresheimer. With the acquisition, Gerresheimer is strengthening its European presence with additional production sites and underpinning its market position as a leading full-service provider and global partner for the pharmaceutical and biotech industries. Gerresheimer expects that the acquisition will have a positive impact on the Group’s Adj. EBITDA margin and Adj. EPS through synergies from the first year onwards. On February 26, 2025, Gerresheimer will publish new guidance for the combined company along with its fiscal year 2024 results.
- Complementary product portfolio and broad coverage with production locations in Europe
- Strengthening the market position as a full-service provider for the pharmaceutical and biotech industry
- Molded glass business is being strategically relaunched
“After the successful completion of the acquisition, we can now concentrate on the integration of Bormioli Pharma into the Gerresheimer Group,” explains Dietmar Siemssen, CEO of Gerresheimer AG. “We are convinced that our customers will benefit from the expansion of the product portfolio and new, integrated systems and solutions.”
Complementary, attractive product portfolio
Bormioli Pharma generated sales of around EUR 371 million in 2023 and an adj. EBITDA margin of around 22%. The company produces pharmaceutical primary packaging made of glass and plastic as well as closure solutions, accessories and dosing systems. In the plastics sector, Bormioli Pharma is one of the leading providers of pharmaceutical plastic systems and solutions. In the glass sector, Bormioli Pharma has an attractive portfolio for parenteral and other pharmaceutical primary packaging.
Molded glass business is being strategically relaunched
The acquisition creates a new, strong Molded Glass unit that has a diversified product portfolio for the pharmaceutical, cosmetics and food and beverage industries. This global entity offers new options for strategic direction for the best growth prospects and competitiveness, which will be evaluated in the coming months.
New forecast for combined company in February 2025
Retroactively to December 1, 2024, the start of the new Gerresheimer financial year 2025, Bormioli Pharma will become part of the Gerresheimer Group and fully consolidated. Therefore, on February 26, 2025, Gerresheimer will publish a new forecast for 2025 and a new medium-term forecast for the combined company together with the results of the 2024 fiscal year.
OTS ORIGINAL TEXT PRESS RELEASE UNDER THE EXCLUSIVE RESPONSIBILITY OF THE SENDER FOR CONTENT – WWW.OTS.AT | EUN